Onxeo Reports its Full-Year 2021 Financial Results and announces additional financing of €12 million
- Cash position of €17.9 million as of December 31, 2021
- Additional financing of €12 million subscribed by historical shareholders Invus and Financière de la Montagne in the form of the issuance of new shares (€8m) and a convertible bond issue (€4m)
- Financial visibility extended to the 2nd quarter of 2023
Paris (France), April 6, 2022 – 6 pm CEST – Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North Copenhagen: ONXEO), hereafter “Onxeo” or the “Company”, a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR), today reported its consolidated results for the fiscal year ending December 31, 2021 and announced additional funding of €12 million subscribed by its longstanding shareholders Invus and Financière de la Montagne.